Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

148.93 +4.34 (+3.00%)
Streaming Delayed Price Updated: 9:46 AM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
3 No-Brainer Stocks to Buy With $200 Right Now
You don't need a mountain of cash to grow your wealth on Wall Street. 
Via The Motley Fool
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Via Benzinga
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Healthcare Stocks
These are the list of healthcare stocks to avoid that present challenges indicating signs of a crash in the near future. 
Via InvestorPlace
Slump Survivors: 3 Stocks That Will Outlast the S&P 500 Downturn
Discover how these stocks may progress in consumer staples, health care, and tech sectors and outperform the S&P 500. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Cutting Edge Picks: 3 Med Tech Stocks With Room to Run
The med tech stocks are worth checking out for value investors seeking potentially overlooked growth catalysts. 
Via InvestorPlace
Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks
Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex Therapeutics evaluates treatment efficacy in patients with suboptimal... 
Via Benzinga
Johnson & Johnson Stock: Buy, Sell, or Hold?
Is this top healthcare stock worth adding to your portfolio today? 
Via The Motley Fool
US Stock: Johnson & Johnson
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. 
Via Talk Markets
Balancing Dividends and Fundamentals: The Case of NYSE:JNJ.
Why JOHNSON & JOHNSON (NYSE:JNJ) is a Top Pick for Dividend Investors. 
Via Chartmill
Johnson & Johnson Is a King of Dividend Safety
The healthcare behemoth has fortified its dividend. 
Via The Motley Fool
7 Retirement Stocks to Buy at a 52-Week Low in April
One of the best ways to keep your portfolio safe while generating income is with dividend-paying retirement stocks at 52-week lows. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for... 
Via Talk Markets
2 Top Growth Stocks to Buy Right Now and Hold Forever
These healthcare stocks can provide enviable long-term portfolio growth. 
Via The Motley Fool
Better Dividend Stock: AbbVie or Johnson & Johnson?
One thing is for sure: Dividend seekers can't go wrong with either. 
Via The Motley Fool
5 Stocks In Focus On Their Recent Dividend Hikes
Wall Street’s impressive bull run for the last 15 months has been facing severe hurdles in April. In such an environment, it may be prudent to consider stocks that consistently deliver dividends. Here... 
Via Talk Markets
7 Stocks to Buy if Inflation Continues to Reign in 2024
The latest inflation readings showed consumers won't get low prices anytime soon, here are seven stocks to buy if inflation continues to rise 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Generational Wealth Builders: 3 Stocks to Own for Decades of Gains
These three long-term stocks to buy promise decades of gains and are poised to enhance your generational wealth. 
Via InvestorPlace
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
Steady Eddies: 7 Rock-Solid Stocks to Anchor Your Portfolio in April
With global markets facing a wave of uncertainty, it’s appropriate for investors to consider these steady stocks. 
Via InvestorPlace
How Much Will $10k Invested in These Dividend Aristocrats Grow to by 2025?
Curious to know how much these dividend aristocrats could grow in the next year? Here's the answer for several well-known shares. 
Via InvestorPlace
The Top 3 Small-Cap Stocks to Buy in April 2024
These top small-cap stocks offer investors diversification across multiple segments but boast a strong standing on their own merits. 
Via InvestorPlace
3 Long-Term Stocks to Buy on the Dip: April 2024
Pounce before it is too late! Build a robust portfolio with these three long-term stocks to buy on the dip. 
Via InvestorPlace
7 blue chip stocks to Buy on the Dip: April 2024
Each of these seven blue-chip stocks to buy on the dip offer high-quality at a more-than-reasonable price. 
Via InvestorPlace
Medtech Marvels: 3 Groundbreaking Medical Device Stocks to Watch in 2024
The medical device market is growing fast, and top medical device firms can become takeover targets. Here are three medtech stocks to watch. 
Via InvestorPlace
Johnson & Johnson Stocks Elliott Wave Technical Analysis
Looking for support as we touched 0.618 Z vs. X. If we find resistance on Medium Level at 150 then we can expected further downside. 
Via Talk Markets
The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth
Discover the top dividend stocks for prolonged wealth in 2024 in pharmaceuticals, integrated telecommunications, drug retail, and tobacco. 
Via InvestorPlace
These Are the 10 High-Profile Stocks U.S. Politicians Have Gravitated to Most Over the Last 3 Years
These stocks kept members of Congress especially busy. 
Via The Motley Fool
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Buying great stocks when they're on sale is a lucrative long-term strategy. 
Via The Motley Fool
Warning! These 3 Blue-Chip Stocks Will Have You Seeing Red
These stocks are underwater right now and likely to remain so as the companies behind them manage serious problems. 
Via InvestorPlace
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.